These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3121273)

  • 21. Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats.
    Yoshida T; Nishioka H; Yoshioka K; Nakano K; Kondo M; Terashima H
    Diabetes; 1987 Jan; 36(1):6-13. PubMed ID: 3025043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of aldose reductase inhibition on motor nerve conduction velocity in diabetic rats.
    Yue DK; Hanwell MA; Satchell PM; Turtle JR
    Diabetes; 1982 Sep; 31(9):789-94. PubMed ID: 6819173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors.
    Jacobson M; Sharma YR; Cotlier E; Hollander JD
    Invest Ophthalmol Vis Sci; 1983 Oct; 24(10):1426-9. PubMed ID: 6413448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24-week controlled trial.
    Fagius J; Brattberg A; Jameson S; Berne C
    Diabetologia; 1985 Jun; 28(6):323-9. PubMed ID: 3930330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurophysiological variables and fibrinolysis in insulin-dependent diabetes treated with an aldose reductase inhibitor or placebo. A double-blind randomized study.
    Jespersen J; Gram J; Christensen JE
    Haemostasis; 1986; 16(6):453-7. PubMed ID: 3108105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical application of aldose reductase inhibitors--prevention and therapy of diabetic complications].
    Hotta N; Sakamoto N
    Nihon Rinsho; 1987 Dec; 45(12):3010-27. PubMed ID: 3128677
    [No Abstract]   [Full Text] [Related]  

  • 27. Effects of aldose reductase inhibitor sorbinil on neuroaxonal dystrophy and levels of myo-inositol and sorbitol in sympathetic autonomic ganglia of streptozocin-induced diabetic rats.
    Schmidt RE; Plurad SB; Sherman WR; Williamson JR; Tilton RG
    Diabetes; 1989 May; 38(5):569-79. PubMed ID: 2497038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement in peripheral nerve function after one year of Sorbinil.
    Gieron MA; Malone JI; Lowitt S; Korthals JK
    Neuroreport; 1991 Jun; 2(6):348-50. PubMed ID: 1655107
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tolrestat for mild diabetic neuropathy. A 52-week, randomized, placebo-controlled trial.
    Giugliano D; Marfella R; Quatraro A; De Rosa N; Salvatore T; Cozzolino D; Ceriello A; Torella R
    Ann Intern Med; 1993 Jan; 118(1):7-11. PubMed ID: 8416161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of glycemic control and aldose reductase inhibition on nerve conduction velocity.
    Pfeifer MA
    Am J Med; 1985 Nov; 79(5A):18-23. PubMed ID: 3934964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of an aldose reductase inhibiting agent on limited joint mobility in diabetic patients.
    Eaton RP; Sibbitt WL; Harsh A
    JAMA; 1985 Mar; 253(10):1437-40. PubMed ID: 3918180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reversal of proteinuria by sorbinil, an aldose reductase inhibitor in spontaneously diabetic (BB) rats.
    Beyer-Mears A; Murray FT; Del Val M; Cruz E; Sciadini M
    Pharmacology; 1988; 36(2):112-20. PubMed ID: 3127836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aldose reductase inhibitors: the end of an era or the need for different trial designs?
    Pfeifer MA; Schumer MP; Gelber DA
    Diabetes; 1997 Sep; 46 Suppl 2():S82-9. PubMed ID: 9285505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overt diabetic neuropathy: repair of axo-glial dysjunction and axonal atrophy by aldose reductase inhibition and its correlation to improvement in nerve conduction velocity.
    Sima AA; Prashar A; Nathaniel V; Bril V; Werb MR; Greene DA
    Diabet Med; 1993 Mar; 10(2):115-21. PubMed ID: 8458187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Galactose cataract prevention with sorbinil, an aldose reductase inhibitor: a light microscopic study.
    Datiles M; Fukui H; Kuwabara T; Kinoshita JH
    Invest Ophthalmol Vis Sci; 1982 Feb; 22(2):174-9. PubMed ID: 6799419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aldose reductase inhibition in diabetes.
    Clarke BF; Young RJ; Martyn CN; Ewing DJ
    Diabet Med; 1984 Jul; 1(2):88-90. PubMed ID: 6242793
    [No Abstract]   [Full Text] [Related]  

  • 37. Medical therapy in the prevention of cataract.
    Brown NA; Bron AJ
    Trans Ophthalmol Soc U K (1962); 1985; 104 ( Pt 7)():748-54. PubMed ID: 3938085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy - a clinical and neurophysiological study.
    Fagius J; Jameson S
    J Neurol Neurosurg Psychiatry; 1981 Nov; 44(11):991-1001. PubMed ID: 6801211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The pathology of diabetic neuropathy and the effects of aldose reductase inhibitors.
    Gillon KR; King RH; Thomas PK
    Clin Endocrinol Metab; 1986 Nov; 15(4):837-53. PubMed ID: 3096616
    [No Abstract]   [Full Text] [Related]  

  • 40. Diabetic neuropathy in the upper limb and the effect of twelve months sorbinil treatment.
    Guy RJ; Gilbey SG; Sheehy M; Asselman P; Watkins PJ
    Diabetologia; 1988 Apr; 31(4):214-20. PubMed ID: 3290018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.